Literature DB >> 24632373

A potential anti-coagulant role of complement factor H.

Janez Ferluga1, Uday Kishore2, Robert B Sim3.   

Abstract

Anti-phospholipid syndrome (APS) is a complex autoimmune disease, associated with recurrent venous and arterial thrombosis in various tissues. APS is associated with specific antibodies against plasma beta-2 glycoprotein 1 (β2-GP1), and these antibodies react with β2-GP1 bound to negatively charged phospholipids (e.g. cardiolipin) on cell membranes. Some APS patients also have autoantibodies to complement factor H (FH), a homologue of β2-GP1, which also binds to anionic phospholipids. β2-GP1 has earlier been shown to inhibit the intrinsic (contact) activated blood coagulation pathway, promoted by anionic phospholipids. Here we examine whether FH could have similar anti-thrombotic properties. In vitro experiments with surface-bound phospholipids and human plasma, in the presence of FH, confirm this hitherto unreported property of FH.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Factor H; anti-phospholipid syndrome; coagulation; complement

Mesh:

Substances:

Year:  2014        PMID: 24632373     DOI: 10.1016/j.molimm.2014.02.012

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

Review 1.  Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.

Authors:  Samuel Deshayes; Nicolas Martin Silva; Valérie Chatelet; Sylvain Chantepie; Moglie Le Quintrec; François Comoz; Frank Bridoux; Marie-Agnès Dragon-Durey; Achille Aouba
Journal:  Clin Rheumatol       Date:  2018-03-07       Impact factor: 2.980

2.  Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina.

Authors:  Gregor Leibundgut; Jun-Hee Lee; Bradley H Strauss; Amit Segev; Sotirios Tsimikas
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

3.  Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H.

Authors:  Cristina Puy; Jiaqing Pang; Stéphanie E Reitsma; Christina U Lorentz; Erik I Tucker; David Gailani; András Gruber; Florea Lupu; Owen J T McCarty
Journal:  J Immunol       Date:  2021-04-15       Impact factor: 5.422

4.  Low Levels of Factor H Family Proteins During Meningococcal Disease Indicate Systemic Processes Rather Than Specific Depletion by Neisseria meningitidis.

Authors:  Anna E van Beek; Richard B Pouw; Victoria J Wright; Neneh Sallah; David Inwald; Clive Hoggart; Mieke C Brouwer; Rachel Galassini; John Thomas; Leo Calvo-Bado; Colin G Fink; Ilse Jongerius; Martin Hibberd; Diana Wouters; Michael Levin; Taco W Kuijpers
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

Review 5.  Complement in the Pathophysiology of the Antiphospholipid Syndrome.

Authors:  Shruti Chaturvedi; Robert A Brodsky; Keith R McCrae
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

6.  Clinical characteristics, inflammation and coagulation status in patients with immunological disease-related chronic cerebrospinal venous insufficiency.

Authors:  Si-Ying Song; Duo Lan; Xiao-Qin Wu; Yu-Chuan Ding; Xun-Ming Ji; Ran Meng
Journal:  Ann Transl Med       Date:  2021-02

7.  Utilizing polymer-conjugate albumin-based ultrafine gas bubbles in combination with ultra-high frequency radiations in drug transportation and delivery.

Authors:  Thi H Le; An H T Phan; Khoa C M Le; Thy D U Phan; Khoi T Nguyen
Journal:  RSC Adv       Date:  2021-10-25       Impact factor: 4.036

Review 8.  Complement in Hemolysis- and Thrombosis- Related Diseases.

Authors:  Shanshan Luo; Desheng Hu; Moran Wang; Peter F Zipfel; Yu Hu
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.